Pfizer Inc. / Bamboo Therapeutics, Inc.

Duchenne Muscular Dystrophy (and rare neuromuscular/CNS gene therapy targets)

Disease Overview

Duchenne muscular dystrophy is an X-linked recessive disorder caused by mutations in the dystrophin gene that produce progressive muscle degeneration, with most boys losing ambulation by their early teens and requiring assisted ventilation by their twenties. Friedreich's ataxia, Canavan disease, and giant axonal neuropathy (GAN) — Bamboo's other targets — are similarly devastating monogenic CNS/neuromuscular conditions affecting only hundreds to a few thousand US patients each, with no curative options at deal time.

Competitive Landscape

In August 2016 the DMD landscape was anchored by Sarepta's just-approved Exondys 51 (eteplirsen, exon-skipping, accelerated approval Sept 2016) and PTC Therapeutics' Translarna (ataluren, EU only). Gene therapy for DMD remained preclinical industry-wide, making Bamboo's miniaturized dystrophin AAV construct one of the earliest credible programs alongside Solid Biosciences and what would become Sarepta's SRP-9001 (Elevidys). Pfizer paid $150M upfront / up to $645M total to vault into the field, picking up a UNC-derived suspension-cell rAAV manufacturing facility in Chapel Hill — a scarce industrial asset. The deal's strategic logic — manufacturing plus four monogenic programs (DMD, Friedreich's ataxia, Canavan, GAN) — was widely viewed as positive at signing (BioPharma Dive, GEN). Outcome was unfavorable: the lead DMD program (later fordadistrogene movaparvovec) suffered a patient death pause in 2021, and in July 2024 Pfizer discontinued the program after the Phase 3 CIFFREO trial missed all endpoints, taking a $230M impairment and laying off 150 staff in Sanford, NC. Sarepta's Elevidys (approved 2023, expanded 2024) became the standard-bearing DMD gene therapy.